Cellbion Q1 2026: Pipeline Progress with Conditional Approval Application for Lu-177-pocuvotide, Operating Loss Widens

Revenue: 612.5 million KRW (up 27.7% YoY from 479.6 million)
Operating loss: 2.44 billion KRW, net loss: 2.40 billion KRW (vs. 1.43 billion each in Q1 2025)
R&D expenses: 1.39 billion KRW (241.3% of revenue)
Lu-177-pocuvotide conditional approval application submitted (Dec 2025); MSD Keytruda combo Phase 1 IND approved
Cash and short-term financial assets: 20.24 billion KRW; debt ratio: 47.72%
Convertible preferred shares issued: 762,859 shares (Apr 2026, capital increase of 381 million KRW)
No share buyback or cancellation; no dividends (accumulated deficit)